China Biologic Products Commences Trading on OTC Bulletin Board
March 04 2008 - 7:00AM
PR Newswire (US)
TAI'AN CITY, China, March 4 /Xinhua-PRNewswire-FirstCall/ -- China
Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO) ("CBP,"
or "the Company"), one of the leading plasma-based pharmaceutical
companies in the People's Republic of China ("PRC"), today
announced that on February 29, 2008, it's common stock was approved
for quotation on the Over-the-Counter Bulletin Board (the "OTCBB")
maintained by the Financial Industry Regulatory Authority (FINRA).
"We are pleased to have our stock quoted on the OTCBB," said Mr.
Stanley Wong, CEO of China Biologic Products. "This is an important
milestone for us as we seek to expand our list of potential
investors and increase both our liquidity and visibility in the
market." The Company's stock is now trading under the symbol
CBPO.OB. About China Biologic Products, Inc. Through its indirect
majority-owned subsidiary Shandong Taibang Biological Products Co.
Ltd., China Biologic Products, Inc. (the "Company"), is principally
engaged in the research, development, production and manufacturing
and sale of plasma-based biopharmaceutical products to hospitals
and other health care facilities in China. The Company's human
albumin products are mainly used to increase blood volume and its
immunoglobulin products are used for the treatment and prevention
diseases. Safe Harbor Statement This release may contain certain
"forward-looking statements" relating to the business of China
Biologic Products, Inc. and its subsidiary companies. All
statements, other than statements of historical fact included
herein are "forward-looking statements," including statements
regarding: the ability of the Company to expand its list of
potential investors and increase its liquidity and visibility in
the market or otherwise achieve its commercial objectives; the
business strategy, plans and objectives of the Company and its
subsidiaries; and any other statements of non-historical
information. These forward-looking statements are often identified
by the use of forward-looking terminology such as "believes,"
"expects" or similar expressions, involve known and unknown risks
and uncertainties. Although the Company believes that the
expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. Investors should
not place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov/). All
forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by
these factors. Other than as required under the securities laws,
the Company does not assume a duty to update these forward-looking
statements. For more information, please contact: Company Contact:
Mr. Stanley Wong, CEO China Biologic Products, Inc. Tel:
+86-538-620-2306 Email: Investor Relations Contact: Mr. Crocker
Coulson, President CCG Elite Investor Relations Tel:
+1-646-213-1915 (NY office) Email: DATASOURCE: China Biologic
Products, Inc. CONTACT: Company Contact: Mr. Stanley Wong, CEO of
China Biologic Products, Inc., +86-538-620-2306, or ; Or Investor
Relations Contact: Mr. Crocker Coulson, President of CCG Elite
Investor Relations, +1-646-213-1915 (NY office), or
Copyright